174 related articles for article (PubMed ID: 20346888)
21. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
[TBL] [Abstract][Full Text] [Related]
22. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
23. Pancytopenia related eosinophilia in rheumatoid arthritis: a specific methotrexate phenomenon?
Bruyn GA; Velthuysen E; Joosten P; Houtman PM
J Rheumatol; 1995 Jul; 22(7):1373-6. PubMed ID: 7562775
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis.
Ohosone Y; Okano Y; Kameda H; Fujii T; Hama N; Hirakata M; Mimori T; Akizuki M; Ikeda Y
J Rheumatol; 1997 Dec; 24(12):2299-303. PubMed ID: 9415631
[TBL] [Abstract][Full Text] [Related]
25. Pancytopenia associated with low dose methotrexate therapy. A regional survey.
al-Awadhi A; Dale P; McKendry RJ
J Rheumatol; 1993 Jul; 20(7):1121-5. PubMed ID: 8371202
[TBL] [Abstract][Full Text] [Related]
26. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
Wolfe F; Michaud K; Stephenson B; Doyle J
J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
[TBL] [Abstract][Full Text] [Related]
27. [A case of pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulphamethoxazole induced pancytopenia].
Shimada T; Nishimura Y; Funada Y; Takenaka K; Kobayashi K; Urata Y; Yosimura S; Nishiuma T; Satouchi M; Yokoyama M
Arerugi; 2004 Jun; 53(6):575-81. PubMed ID: 15247519
[TBL] [Abstract][Full Text] [Related]
28. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
[TBL] [Abstract][Full Text] [Related]
29. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
Kent PD; Luthra HS; Michet C
J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate induced pancytopenia is rare and concern for it should not limit its use.
Yazici Y
Rheumatology (Oxford); 2006 Mar; 45(3):361; author reply 363-4. PubMed ID: 16332954
[No Abstract] [Full Text] [Related]
32. Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate.
Cheung KK; Chow KM; Szeto CC; Tai MH; Kwan BC; Li PK
J Clin Rheumatol; 2009 Jun; 15(4):177-80. PubMed ID: 19502905
[TBL] [Abstract][Full Text] [Related]
33. Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects.
Andersen LS; Hansen EL; Knudsen JB; Wester JU; Hansen GV; Hansen TM
J Rheumatol; 1997 May; 24(5):830-7. PubMed ID: 9150068
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous ulceration as a sign of methotrexate toxicity.
Del Pozo J; Martínez W; García-Silva J; Almagro M; Peña-Penabad C; Fonseca E
Eur J Dermatol; 2001; 11(5):450-2. PubMed ID: 11525955
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?
Vincent S; Slease RB; Rocca PV
Del Med J; 2002 Dec; 74(12):469-73. PubMed ID: 15595320
[TBL] [Abstract][Full Text] [Related]
36. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions.
Kinder AJ; Hassell AB; Brand J; Brownfield A; Grove M; Shadforth MF
Rheumatology (Oxford); 2005 Jan; 44(1):61-6. PubMed ID: 15611303
[TBL] [Abstract][Full Text] [Related]
37. Methotrexate induced neutropenia associated with coprescription of penicillins: serious and under-reported?
Sathi N; Ackah J; Dawson J
Rheumatology (Oxford); 2006 Mar; 45(3):361-2; author reply 363-4. PubMed ID: 16332953
[No Abstract] [Full Text] [Related]
38. [Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy].
Xie QB; Wen FQ; Yin G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):138-40. PubMed ID: 19292064
[TBL] [Abstract][Full Text] [Related]
39. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
[TBL] [Abstract][Full Text] [Related]
40. Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event.
Marshall RW; Marshall VJ; Hull R
Rheumatology (Oxford); 2006 Mar; 45(3):362-3; author reply 363-4. PubMed ID: 16332952
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
